These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 27307418)

  • 21. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
    Protsenko SA; Rudakova AV
    Vopr Onkol; 2015; 61(4):676-80. PubMed ID: 26571844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serono pays $44m to settle promotion of multiple sclerosis drug.
    Tanne JH
    BMJ; 2011 May; 342():d2922. PubMed ID: 21558361
    [No Abstract]   [Full Text] [Related]  

  • 23. US pharma company fined 435 million dollars.
    McLaughlin P
    CMAJ; 2006 Oct; 175(9):1046. PubMed ID: 17060646
    [No Abstract]   [Full Text] [Related]  

  • 24. Experience with erlotinib in the treatment of non-small cell lung cancer.
    Landi L; Cappuzzo F
    Ther Adv Respir Dis; 2015 Aug; 9(4):146-63. PubMed ID: 26063687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
    Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
    Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calls to suspend European sales of erlotinib for lung cancer.
    Tanday S
    Lancet Respir Med; 2016 Sep; 4(9):691. PubMed ID: 27492661
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
    Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
    Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies.
    Atagi S; Goto K; Seto T; Yamamoto N; Tamura T; Tajima K; Inagaki N
    Future Oncol; 2016 Sep; 12(18):2117-26. PubMed ID: 27267081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
    Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
    Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
    Klughammer B; Brugger W; Cappuzzo F; Ciuleanu T; Mok T; Reck M; Tan EH; Delmar P; Klingelschmitt G; Yin AY; Spleiss O; Wu L; Shames DS
    J Thorac Oncol; 2016 Apr; 11(4):545-55. PubMed ID: 26773740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
    Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients.
    Arrieta O; Rios Trejo MA; Michel RM
    J Thorac Oncol; 2009 Aug; 4(8):1043. PubMed ID: 19633484
    [No Abstract]   [Full Text] [Related]  

  • 33. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
    Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
    J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted lung cancer therapies.
    Farmer G
    Nat Rev Drug Discov; 2004 Jul; 3(7):547-8. PubMed ID: 15272497
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer.
    Printz C
    Cancer; 2015 Oct; 121(20):3562-3. PubMed ID: 26431439
    [No Abstract]   [Full Text] [Related]  

  • 36. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
    Nadler E; Forsyth M; Satram-Hoang S; Reyes C
    J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.
    Deplanque G; Gervais R; Vergnenegre A; Falchero L; Souquet PJ; Chavaillon JM; Taviot B; Fraboulet G; Saal H; Robert C; Chosidow O;
    J Am Acad Dermatol; 2016 Jun; 74(6):1077-85. PubMed ID: 26946985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
    Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
    Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
    Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
    Bogdanowicz BS; Hoch MA; Hartranft ME
    J Oncol Pharm Pract; 2017 Apr; 23(3):203-214. PubMed ID: 26911477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.